Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) FCF Margin (2020 - 2025)

Caribou Biosciences has reported FCF Margin over the past 6 years, most recently at 562.07% for Q4 2025.

  • Quarterly FCF Margin rose 97197.0% to 562.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1006.82% through Dec 2025, up 38355.0% year-over-year, with the annual reading at 1006.82% for FY2025, 38355.0% up from the prior year.
  • FCF Margin was 562.07% for Q4 2025 at Caribou Biosciences, up from 1080.85% in the prior quarter.
  • Over five years, FCF Margin peaked at 1279.38% in Q1 2021 and troughed at 1820.55% in Q3 2024.
  • The 5-year median for FCF Margin is 882.02% (2021), against an average of 818.2%.
  • Year-over-year, FCF Margin tumbled -212007bps in 2022 and then surged 97197bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 908.25% in 2021, then grew by 24bps to 690.95% in 2022, then crashed by -32bps to 911.64% in 2023, then tumbled by -68bps to 1534.04% in 2024, then skyrocketed by 63bps to 562.07% in 2025.
  • Per Business Quant, the three most recent readings for CRBU's FCF Margin are 562.07% (Q4 2025), 1080.85% (Q3 2025), and 1109.97% (Q2 2025).